QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Related Article All Versions of this Article: mol.106.025932v1 70/1/1    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Related articles in MolPharm Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beinborn, M. Search for Related Content PubMed PubMed Citation Articles by Beinborn, M.

Perspective

Class B GPCRs: A Hidden Agonist Within?

Molecular Pharmacology Research Center, Molecular Cardiology Research Institute, Tufts-New England Medical Center, Boston, Massachusetts

Class B G protein-coupled receptors (GPCRs) regulate a wide range of endocrine and neuroendocrine functions and are endogenously stimulated by moderately large peptide hormones. Current evidence suggests that the carboxyl termini of cognate peptides bind to the amino terminus of their G protein-coupled receptors (GPCRs) and that the peptides' amino terminal segments then dock to the heptahelical receptor portion to induce signaling. In this issue of Molecular Pharmacology, Dong et al. (p. 206) propose an alternative model of ligand-induced class B GPCR activation. Based primarily on studies with the secretin receptor, a prototype class B family member, they provide evidence that the endogenous peptide hormone does not function as an activator per se. Instead, this hormone (secretin) exposes a hidden, built-in agonist epitope that is present within the amino terminus of its target GPCR. Isolated oligopeptide fragments containing this epitope act as full agonists on the secretin receptor despite their lack of amino acid homology with the secretin hormone. These nonconventional agonists can be minimized to tripeptide molecules and still maintain biological activity. The study to be discussed introduces a novel paradigm of class B GPCR function, and may facilitate the elusive goal of finding small molecule agonist drugs for this therapeutically attractive group of receptors.

Address correspondence to: Dr. Martin Beinborn, Molecular Pharmacology Research Center, Molecular Cardiology Research Institute, Tufts-New England Medical Center, 15 Kneeland Street, Boston, MA 02111. E-mail: mbeinborn{at}tufts-nemc.org

Related articles in MolPharm:

Possible Endogenous Agonist Mechanism for the Activation of Secretin Family G Protein-Coupled Receptors

Maoqing Dong, Delia I. Pinon, Yan W. Asmann, and Laurence J. Miller
MolPharm 2006 70: 206-213. [Abstract] [Full Text]  

This article has been cited by other articles:

				M. Bruysters, M. Verhoef-Post, and A. P. N. Themmen Asp330 and Tyr331 in the C-terminal Cysteine-rich Region of the Luteinizing Hormone Receptor Are Key Residues in Hormone-induced Receptor Activation J. Biol. Chem., September 19, 2008; 283(38): 25821 - 25828. [Abstract] [Full Text] [PDF]

				T. Sugiura, Y. Kato, T. Wakayama, D. L. Silver, Y. Kubo, S. Iseki, and A. Tsuji PDZK1 Regulates Two Intestinal Solute Carriers (Slc15a1 and Slc22a5) in Mice Drug Metab. Dispos., June 1, 2008; 36(6): 1181 - 1188. [Abstract] [Full Text] [PDF]